UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2019
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
|
|
14 Plaza Drive Latham, New York 12110
|
|||
|
(Address of Principal Executive Offices) (Zip Code)
|
|||
|
(518) 795-1400
|
|||
|
(Registrant’s telephone number, including area code)
|
|||
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered |
|
Common Stock, par value $0.01 per share
|
ANGO
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 – Submission of Matters to a Vote of Security Holders.
(a) The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on October 15, 2019.
(b) Shareholders of AngioDynamics voted on the matters set forth below.
|
|
1.
|
The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2022 Annual Meeting of Shareholders of
AngioDynamics and until their respective successors are duly elected and qualified, based upon the following votes:
|
|
Nominee
|
Votes For
|
Withheld
|
Broker Non-Votes
|
|
|
Kevin J. Gould
|
32,487,844
|
690,644
|
1,549,397
|
|
|
Dennis S. Meteny
|
32,163,154
|
1,015,334
|
1,549,397
|
|
|
Michael E. Tarnoff, MD
|
32,669,038
|
509,450
|
1,549,397
|
|
|
2.
|
The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2020
was approved based upon the following votes:
|
|
Votes for approval
|
34,647,230
|
|||
|
Votes against
|
31,517
|
|||
|
Abstentions
|
49,138
|
|||
|
There were no broker non-votes for this item.
|
||||
|
|
3.
|
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:
|
|
Votes for approval
|
32,610,524
|
|||
|
Votes against
|
511,361
|
|||
|
Abstentions
|
56,603
|
|||
|
Broker non-votes
|
1,549,397
|
(c) Not applicable.
(d) Not applicable.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| ANGIODYNAMICS, INC. | |||
| (Registrant) |
|||
|
Date: October 18, 2019
|
By:
|
/s/ Stephen A. Trowbridge | |
| Stephen A. Trowbridge | |||
| Senior Vice President and General Counsel | |||